Teva Guides for Disappointment

Teva Pharmaceuticals (NYSE: TEVA  ) released its full-year 2013 forecast, which missed top-line estimates by 4% and bottom-line estimates by 11%. The markets haven't taken the news too badly, opening down 3% but rallying back during the day to a slight gain. In this video, Motley Fool health care analyst David Williamson tells us where these low figures may have come from and what Teva may have in store for 2013.

One rumor suggests that Teva may be looking to acquire additional branded drugs including Amarin's new triglyceride-lowering drug Vascepa. Amarin has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 02, 2012, at 7:57 PM, JPB8353 wrote:

    Geez!!! Stop posting articles like this a news. They are only thinly disguised advertisements. And annoying at that.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2134813, ~/Articles/ArticleHandler.aspx, 11/27/2014 4:13:10 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement